First Trust NYSE Arca Biotechnology Index Fund (FBT)

NYSEARCA: FBT · Real-Time Price · USD
164.94
+2.51 (1.55%)
Nov 20, 2024, 4:00 PM EST - Market closed
1.55%
Assets $1.11B
Expense Ratio 0.56%
PE Ratio 19.24
Shares Out 6.85M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return +18.20%
Volume 24,976
Open 163.05
Previous Close 162.43
Day's Range 162.60 - 165.09
52-Week Low 137.97
52-Week High 179.67
Beta 0.66
Holdings 32
Inception Date Jun 19, 2006

About FBT

Fund Home Page

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol FBT
ETF Provider First Trust
Index Tracked NYSE Arca Biotechnology Index

Top 10 Holdings

39.72% of assets
Name Symbol Weight
Exelixis, Inc. EXEL 4.67%
Natera, Inc. NTRA 4.18%
Incyte Corporation INCY 4.13%
Corcept Therapeutics Incorporated CORT 4.11%
ACADIA Pharmaceuticals Inc. ACAD 4.05%
Intra-Cellular Therapies, Inc. ITCI 3.86%
argenx SE ARGX 3.75%
Gilead Sciences, Inc. GILD 3.69%
Catalyst Pharmaceuticals, Inc. CPRX 3.66%
Neurocrine Biosciences, Inc. NBIX 3.61%
View More Holdings

News

FBT: An Equal Weight Way To Play Biotech

Biotech stocks have not regained their 2021 peak levels, making them a potential catch-up trade. First Trust NYSE Arca Biotechnology Index Fund ETF is a fund that replicates the performance of the NYS...

8 months ago - Seeking Alpha

Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar

Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.

1 year ago - Market Watch

FBT: No Great Prospects Despite Huge Price Gain Over Past One Year

Most stocks in FBT's biotechnology portfolio beat returns of S&P 500 during the past one year. FBT also registered a price growth of 15.5 percent. However, over the past five months, return has been m...

1 year ago - Seeking Alpha

The Fall Of SVB: What It Means For Healthcare Startups

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

Other symbols: BBCBBHIBBIHEIHFIHIIYH
1 year ago - Seeking Alpha

Can Health Care Stocks Outperform Again In 2023?

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

2 years ago - Seeking Alpha

Why Now Could Be The Time To Consider Neuroscience Investments

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...

2 years ago - Seeking Alpha

FBT: This Biotech ETF Is Better Avoided In The Short Term

FBT doesn't pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months.

2 years ago - Seeking Alpha

FBT: A Long Term Hold If Done With Effective Hedging

FBT is a passive biotechnology ETF, which doesn't pay any dividend. Baring the past one year, FBT's price return has outperformed the S&P 500.

2 years ago - Seeking Alpha

Biotechs Ready To Roar

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotec...

3 years ago - Seeking Alpha

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical dec...

Other symbols: BIIBBBHIBBPBEPKW
3 years ago - Benzinga

Biotech Innovations Remain At Forefront

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...

3 years ago - Seeking Alpha

Moving Beyond COVID In Biopharma

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...

3 years ago - Seeking Alpha

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...

Other symbols: BBHPBE
4 years ago - Benzinga

Biotech ETFs at multi-week highs, extending winning streak

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...

Other symbols: BBHIBBXBI
4 years ago - Market Watch

Biotech ETFs at two-week highs on upbeat vaccine news

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...

Other symbols: ARKGSBIO
4 years ago - Market Watch

Election History Says Buy Biotech Dip

Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...

4 years ago - Benzinga

Post-Pandemic Stars Could Align For This Biotech ETF

These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.

4 years ago - Benzinga

Coronavirus Sparked Healthcare ETFs In General, But Ultimately, We Really Do Need To Pick And Choose

Coronavirus Sparked Healthcare ETFs In General, But Ultimately, We Really Do Need To Pick And Choose

Other symbols: IBBIHFPJPXBIXLV
4 years ago - Seeking Alpha

How To Avoid The Worst Sector ETFs: Q4 2019

How To Avoid The Worst Sector ETFs: Q4 2019

5 years ago - Seeking Alpha

Biotech stocks fall after Trump promises executive order drug prices

CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.

5 years ago - CNBC Television

Is now the time to buy Nike? What about biotech? #AskHalftime

The "Halftime Report" traders take viewer questions on Nike and biotech.

Other symbols: IBBNKEXBI
6 years ago - CNBC Television